Folegatti Pedro M, Bellamy Duncan, Roberts Rachel, Powlson Jonathan, Edwards Nick J, Mair Catherine F, Bowyer Georgina, Poulton Ian, Mitton Celia H, Green Nicky, Berrie Eleanor, Lawrie Alison M, Hill Adrian V S, Ewer Katie J, Hermon-Taylor John, Gilbert Sarah C
The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK.
Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK.
Vaccines (Basel). 2019 May 15;7(2):40. doi: 10.3390/vaccines7020040.
Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widespread seroprevalence of neutralising antibodies. We have constructed a replication deficient simian adenovirus-vectored vaccine (ChAdOx2) expressing 4 genes from the subspecies (, , and ). Safety and T-cell immunogenicity results of the first clinical use of the ChAdOx2 vector are presented here. The trial was conducted using a 'three-plus-three' dose escalation study design. We demonstrate the vaccine is safe, well tolerated and immunogenic.
腺病毒载体疫苗是诱导细胞免疫反应的一种高效策略，对细胞内病原体特别有效。开发重组猿猴腺病毒载体是为了规避因中和抗体广泛存在血清阳性率而使用人腺病毒所带来的限制。我们构建了一种复制缺陷型猿猴腺病毒载体疫苗（ChAdOx2），它表达来自该亚种的4个基因（、、和）。本文展示了ChAdOx2载体首次临床应用的安全性和T细胞免疫原性结果。该试验采用“3+3”剂量递增研究设计进行。我们证明该疫苗是安全的，耐受性良好且具有免疫原性。
Zotero 插件
